newsfilter
← Latest News
GlobeNewswire·

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for